Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Abstract
PMID
Authors John R. MacDougall; John Bradley; Raymond Mak; Neil Dhawan; Wei Chen
Title Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 83 Supplement 7 April 1, 2023
URL https://aacrjournals.org/cancerres/article/83/7_Supplement/4946/724920/Abstract-4946-TOS-358-a-first-in-class-covalent
Abstract Text PI3Kα is frequently mutated in a variety of cancer types, and the PI3K-AKT signaling axis also plays a role in insulin signaling and glucose homeostasis. TOS-358 is a highly selective first-in-class covalent inhibitor of PI3Kα and is currently in clinical development in multiple solid malignancies. Interestingly, TOS-358 potently and specifically inhibits PI3Kα deeply and durably, but does not induce significant hyperglycemia in a variety of animal models. TOS-358 has consistently demonstrated superior efficacy comparing to reversible PI3Kα inhibitors (ATP-competitive and Allosteric) across 30+ different PDX and CDX mutant PI3Kα dependent cancer models. Detailed metabolic studies also revealed TOS-358 does not induce significant hyperglycemia effects in mice, rats and dogs at efficacious doses, which mirrors previous finding that show that PI3Kα knockout does not induce significant hyperglycemia. Furthermore, we elucidate that previous reversible PI3Kα inhibitors lead to dramatic hyperglycemia due to their potent inhibition of multiple PI3K isoforms at effective concentrations of the molecules in a cellular setting. This data reveals that highly specific and potent covalent inhibition of PI3Kα leads to dramatically superior efficacy and an improved safety profile.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PIK3CA mutant Advanced Solid Tumor predicted - sensitive TOS-358 Preclinical - Pdx Actionable In a preclinical study, TOS-358 demonstrated efficacy in patient-derived xenograft (PDX) and cell line xenograft models harboring PIK3CA mutations (Cancer Res (2023) 83 (7_Supplement): 4946). detail...